Corbus Pharmaceuticals Holdings Inc Stock

$50.04

1.44% day before yesterday

Nasdaq, Sep 06, 10:00 pm CET

ISIN

US21833P1030

Symbol

CRBP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Corbus Pharmaceuticals Holdings Inc Stock price

$50.04

-113.46 69.39% 5Y

Nasdaq, Closing price Fri, Sep 06 2024

-0.73 1.44%

ISIN

US21833P1030

Symbol

CRBP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$602.68m
Enterprise Value	$470.17m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	4.58
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-40.20m
Free Cash Flow (TTM) Free Cash Flow	$-30.10m
Cash position	$147.31m
EPS (TTM) EPS	$-5.82
P/E forward	negative
Short interest	12.16%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Corbus Pharmaceuticals Holdings Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Corbus Pharmaceuticals Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.65 0.65	49% 49% -
Gross Profit	-0.65 -0.65	49% 49% -
- Selling and Administrative Expenses	13 13	9% 9% -
- Research and Development Expense	26 26	7% 7% -
EBITDA	-40 -40	8% 8% -
- Depreciation and Amortization	0.65 0.65	49% 49% -
EBIT (Operating Income) EBIT	-40 -40	10% 10% -
Net Profit	-35 -35	24% 24% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Corbus Pharmaceuticals Holdings Inc Stock News

Positive

Market Watch

●

12 days ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.

Neutral

GlobeNewsWire

●

18 days ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee.

Neutral

GlobeNewsWire

●

about one month ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024.

More Corbus Pharmaceuticals Holdings Inc News

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Head office	United States
CEO	Yuval Cohen
Employees	19
Founded	2009
Website	www.corbuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now